Holen Sie sich die Stockscreener-App
82.45
1.10%
0.90
Handel nachbörslich:
82.45
Schlusskurs vom Vortag:
$81.55
Offen:
$82.61
24-Stunden-Volumen:
266.03K
Relative Volume:
0.60
Marktkapitalisierung:
$1.21B
Einnahmen:
$1.30M
Nettoeinkommen (Verlust:
$-130.19M
KGV:
-9.8274
EPS:
-8.3898
Netto-Cashflow:
$-131.94M
1W Leistung:
-1.95%
1M Leistung:
-13.04%
6M Leistung:
+12.19%
1J Leistung:
+257.24%
1-Tages-Spanne:
$81.01
$86.14
1-Wochen-Bereich:
$81.01
$90.00
52-Wochen-Spanne:
$20.55
$155.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Firmenname
Inhibrx Biosciences Inc
Sektor
Branche
Telefon
(858) 795-4220
Adresse
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
82.45 | 1.20B | 1.30M | -130.19M | -131.94M | -8.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-08 | Eingeleitet | Stifel | Buy |
| 2024-07-23 | Eingeleitet | JMP Securities | Mkt Perform |
| 2024-01-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-09-21 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Inhibrx Biosciences Inc Aktie (INBX) Neueste Nachrichten
Inhibrx Biosciences urges expanded research to address unmet needs in head and neck cancer - Traders Union
TradingKey - TradingKey
Inhibrx Biosciences, Inc. Revenue Breakdown – NASDAQ:INBX - TradingView
Inhibrx Biosciences Inc (INBX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inhibrx Biosciences Inc (INBX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Inhibrx Biosciences: The Whole Story Rides On INBRX-106 (NASDAQ:INBX) - Seeking Alpha
INBX|Inhibrx Biosciences Inc|Price:81.550|Chg%:-3.450 - TradingKey
Ongoing studies in rare cancer gain traction for Inhibrx Biosciences amid urgent patient needs - Traders Union
Inhibrx Biosciences Inc (INBX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price-Driven Insight from (INBX) for Rule-Based Strategy - Stock Traders Daily
Does Inhibrx Biosciences' (INBX) Expanded Credit Facility Quietly Redefine Its Risk‑Reward Profile? - Sahm
Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act (NASDAQ:INBX) - Seeking Alpha
Inhibrx Biosciences Expands Credit Facility to $500 Million - TipRanks
Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 million - Bitget
Inhibrx Biosciences Secures $500 Million Credit Facility with Oxford Finance to Accelerate Clinical Pipeline Expansion - Minichart
Inhibrx expands credit facility to $500 million with Oxford By Investing.com - Investing.com South Africa
Inhibrx Biosciences Expands Oxford Credit Facility to $500 Million, Draws $100 Million, Issues Warrants - TradingView
Inhibrx Biosciences (Nasdaq: INBX) secures up to $500M Oxford credit - Stock Titan
Inhibrx Shares Fall After Expanding Loan Agreement to $500M - Moomoo
Inhibrx expands credit facility to $500 million with Oxford - Investing.com
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million - PR Newswire
What is Inhibrx Biosciences, Inc. (INBX) stock_business overview_development history - Bitget
Are you looking for a top momentum pick? Why Inhibrx Biosciences, Inc. (INBX) is a great choice - MSN
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice - Yahoo Finance
Top Cybin (HELP) Competitors 2026 - MarketBeat
INBX Q1 2026 Earnings: Wider-than-Expected Loss Despite Modest Stock GainEarnings Growth Analysis - dars.gov.et
Inhibrx Biosciences (INBX) Stock Analysis Report | Financials & Insights - Benzinga España
How Russell Index Reclassification Toward Growth Benchmarks Will Impact Inhibrx Biosciences (INBX) Investors - simplywall.st
(INBX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell 2000 Defensive Index - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 2500 Growth Benchmark - marketscreener.com
INBX Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Company Reports No Revenue - dars.gov.et
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 2000 Growth Benchmark - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 3000E Growth Benchmark - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell Microcap Index - marketscreener.com
Inhibrx Biosciences, Inc.(NasdaqGS:INBX) dropped from Russell 2000 Value-Defensive Index - marketscreener.com
Inhibrx Biosciences (INBX) Wins FDA Filing Acceptance, Is More Upside Already Priced In? - Sahm
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell 3000E Value Benchmark - marketscreener.com
Enterprise value to revenue forward of Inhibrx Biosciences, Inc. – NASDAQ:INBX - TradingView
Price to sales forward of Inhibrx Biosciences, Inc. – NASDAQ:INBX - TradingView
INBX News | INHIBRX BIOSCIENCES INC (NASDAQ:INBX) - ChartMill
Inhibrx Biosciences urges continued research to address unmet needs in rare cancer treatment - Traders Union
Inhibrx Biosciences, Inc. Actuals & Estimates (NASDAQ:INBX) - TradingView
INBX Forecast — Price Target — Prediction for 2027 - TradingView
Inhibrx Biosciences Inc (INBX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & More - RTTNews
The Bull Case For Inhibrx Biosciences (INBX) Could Change Following FDA BLA Acceptance For Ozekibart - Sahm
INBX Stock Hit Record Highs: Retail Turns ‘Extremely Bullish’ On This Cancer Play - Stocktwits
INBX Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline AdvancesEarnings Sentiment Score - dars.gov.et
INBX Q1 2026 Earnings: EPS Misses Estimates Amid Continued R&D InvestmentCapex Guidance - DonanımHaber
(INBX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Finanzdaten der Inhibrx Biosciences Inc-Aktie (INBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):